MALVERN, Pa., Nov. 7, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the appointment of Mary Ann Gray, Ph.D. and Mr. Michael D. Kishbauch as Class I directors to fill two board slots that have been vacant since January 2014.
"Dr. Gray is an experienced corporate director for both public and private companies with a strong dual background as a scientist as well as an analyst and portfolio manager for over $1 billion in healthcare investments. The public and private boards on which she has served encompass every stage of development from pre-clinical to commercial. Mr. Kishbauch is a senior business executive experienced in pharmaceutical, biotechnology, consumer packaged goods and agency businesses with significant product and company launch experience. Both will add valuable experience and expertise to our Board of Directors," said J. Kevin Buchi, President and Chief Executive Officer of TetraLogic.
Since 2003, Dr. Gray has served as President of Gray Strategic Advisors, LLC, which provides strategic consulting services to the biotechnology industry. From 1999 to 2003, Dr. Gray was Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund. Prior to 1999, Dr. Gray led biotechnology equity research groups at Raymond James & Associates, Warburg Dillon Read, and Kidder Peabody. Dr. Gray currently serves on the Boards of Directors of three other publicly traded biopharmaceutical companies, Dyax Corp., Acadia Pharmaceuticals, Inc., and Senomyx, Inc.
Mr. Kishbauch served as the Chief Executive Officer and President of Achillion Pharmaceuticals, Inc., from July 2004 to May 2013. Prior to joining Achillion, he founded and served as President and CEO of OraPharma, Inc., a publicly-traded, commercial-stage pharmaceutical company focused on oral health care, which was acquired by Johnson & Johnson. Prior to OraPharma, Inc., Mr. Kishbauch held senior management positions with MedImmune, Inc., including serving as President and COO. Before that, Mr. Kishbauch was at Ciba-Geigy where he spent a total of 11 years launching and commercializing products. He currently serves on the Board of Directors of Achillion.
About TetraLogic Pharmaceuticals Corporation
TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. TetraLogic has two clinical-stage product candidates in development: birinapant and SHAPE. Birinapant is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors, and is also being tested in a Phase 1b/2a clinical trial in hepatitis B. SHAPE is entering a Phase 2 clinical trial for early-stage Cutaneous T-cell Lymphoma.
Some of the statements in this release are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events or TetraLogic's pre-clinical and clinical development of birinapant, SHAPE and other clinical programs, future expectations, plans and prospects. Although TetraLogic believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. TetraLogic has attempted to identify forward looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the heading "Risk Factors" in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 19, 2014 and in our form 10-Q filed with the SEC on November 5, 2014. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CONTACT: Company Contact: Pete A. Meyers Chief Financial Officer and Treasurer TetraLogic Pharmaceuticals Corporation (610) 889 - 9900, x103 Pete.email@example.com Investor Relations Contact: Ami Bavishi Burns McClellan, Inc. (212)-213-0006 firstname.lastname@example.org